Oklahoma City, OK, United States of America

Russell P Rother

This inventor holds 38 USPTO granted patents and 23 published patent applications, plus 9 CIPO patents and 13 EPO patents, primarily in Complement Therapeutics. Top assignees: Alexion Pharmaceuticals, Inc., Oklahoma Medical Research Foundation, Selexys Pharmaceuticals Corporation. Active years: 1996-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Russell P Rother. Retrieved from https://idiyas.com/inventor/russell-p-rother

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 38 (Patent Applications = 23)

% Patents Active = 89.5

CIPO Patents = 9 (Patent Applications = 11)

EPO Patents = 13 (Patent Applications = 30)

Average Co-Inventor Count = 2.9

ph-index = 10

Forward Citations = 485(Granted Patents)

Location History:

Cheshire, CT (US) (1996 - 2002)
Prospect, CT (US) (2008 - 2011)
Oklahoma, OK (US) (2016)
Oklahoma City, OK (US) (2011 - 2023)

Company Filing History:

36 out of 199

Alexion Pharmaceuticals, Inc.

patents

2 out of 200

Oklahoma Medical Research Foundation

patents

2 out of 5

Selexys Pharmaceuticals Corporation

patents

where one patent can have more than one assignee

Years Active: 1996-2023

Loading Chart...

Areas of Expertise:

Complement Disorders

Anti-C5A Antibodies

Paroxysmal Nocturnal Hemoglobinuria

Thrombotic Conditions

Hybrid Antibodies

CD200 Antibodies

Inflammatory Diseases

E-selectin Antibodies

Retroviral Vectors

Complement Inhibitors

Nucleic Acids

Therapeutic Methods

38 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11807678 - Methods and compositions for treating complement-associated disorders (2023-11-07),

2. 11407821 - Anti-C5A antibodies (2022-08-09),

3. 11112402 - Reagents and methods for detecting PNH type II white blood cells and their identification as risk factors for thrombotic disorders (2021-09-07),

4. 10703809 - Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement (2020-07-07),

5. 10590189 - Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement (2020-03-17),

6. 10450370 - Anti-C5a antibodies (2019-10-22),

7. 10126293 - Reagents and methods for detecting PNH type II white blood cells and their identification as risk factors for thrombotic disorders (2018-11-13),

8. 9963503 - Methods of producing anti-C5a antibodies (2018-05-08),

9. 9862767 - Therapeutic methods using anti-CD200 antibodies (2018-01-09),

10. 9771418 - Methods for treating complement-associated disorders (2017-09-26),

11. 9732149 - Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement (2017-08-15),

12. 9725504 - Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement (2017-08-08),

13. 9718880 - Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement (2017-08-01),

14. RE46323 - Antibodies to OX-2/CD200 and uses thereof in inhibiting immune responses (2017-02-27),

15. 9469690 - Methods of treating complement-associated disorders with anti-C5a antibodies (2016-10-18),

Title: Innovations by Russell P Rother in the Field of Complement-Associated Disorders

Introduction

Russell P Rother is an accomplished inventor based in Oklahoma City, Oklahoma. With an impressive portfolio of 38 patents, Rother has made significant contributions to the field of medical science, particularly in the area of complement-associated disorders. His inventions are paving the way for new treatment methods that employ innovative compositions and methodologies.

Latest Patents

Among his latest patents, Rother's work focuses on "Methods and compositions for treating complement-associated disorders." This patent discloses compositions that contain inhibitors of the human complement system, which are critical for treating or preventing various complement-related health issues. In some embodiments, these inhibitors are administered chronically to patients to maintain systemic complement inhibition and prevent breakthrough symptoms. Additionally, he has developed anti-C5A antibodies that can target the human complement component C5, addressing disorders such as atypical hemolytic uremic syndrome, age-related macular degeneration, and several other serious conditions.

Career Highlights

Rother has directed his expertise toward serving in prominent roles at leading pharmaceutical companies. Notably, he has worked with Alexion Pharmaceuticals, Inc., and Selexys Pharmaceuticals Corporation, where his groundbreaking research has gained attention in the medical community. His career is marked by a commitment to innovation and a drive to find solutions for complex health issues.

Collaborations

Throughout his career, Rother has collaborated with notable individuals including Douglas L. Sheridan and Paul P. Tamburini. These partnerships have significantly enhanced the impact of his research, as collaborative efforts often lead to more refined and effective innovations.

Conclusion

Russell P Rother's contributions to the field of medicine through his extensive patent portfolio are remarkable. His work not only exemplifies innovation in treating complement-associated disorders but also highlights the significance of collaboration in advancing medical science. As he continues to build on his previous accomplishments, the medical community eagerly anticipates future developments from this prolific inventor.

Profile summary based on public USPTO records.